TY  - JOUR
A1  - Herbert, S. L.
A1  - Wöckel, A.
A1  - Kreienberg, R.
A1  - Kühn, T.
A1  - Flock, F.
A1  - Felberbaum, R.
A1  - Janni, W.
A1  - Curtaz, C.
A1  - Kiesel, M.
A1  - Stüber, T.
A1  - Diessner, J.
A1  - Salmen, J.
A1  - Schwentner, L.
A1  - Fink, V.
A1  - Bekes, I.
A1  - Leinert, E.
A1  - Lato, K.
A1  - Polasik, A.
A1  - Schochter, F.
A1  - Singer, S.
T1  - To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis?
JF  - Breast Cancer Research and Treatment
N2  - Objective
In this study, we investigated to which extent patients feel well informed about their disease and treatment, which areas they wish more or less information and which variables are associated with a need for information about the disease, medical tests and treatment.

Methods
In a German multi-centre prospective study, we enrolled 759 female breast cancer patients at the time of cancer diagnosis (baseline). Data on information were captured at 5 years after diagnosis with the European Organisation for Research and Treatment of Cancer (EORTC) Information Module (EORTC QLQ-INFO24). Good information predictors were analysed using linear regression models.

Results
There were 456 patients who participated at the 5-year follow-up. They reported to feel well informed about medical tests (mean score 78.5) and the disease itself (69.3) but relatively poorly about other services (44.3) and about different places of care (31.3). The survivors expressed a need for more information concerning: side effects and long-term consequences of therapy, more information in general, information about aftercare, prognosis, complementary medicine, disease and therapy. Patients with higher incomes were better informed about medical tests (β 0.26, p 0.04) and worse informed with increasing levels of fear of treatment (β − 0.11, p 0.02). Information about treatment was reported to be worse by survivors > 70 years old (β -0.34, p 0.03) and by immigrants (β -0.11, p 0.02). Survivors who had received additional written information felt better informed about disease, medical tests, treatment and other services (β 0.19/0.19/0.20/0.25; each p < 0.01).

Conclusion
Health care providers have to reconsider how and what kind of information they provide. Providing written information, in addition to oral information, may improve meeting those information needs.
KW  - breast cancer
KW  - survivors
KW  - unmet needs
KW  - health care providers
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-232356
SN  - 0167-6806
VL  - 185
ER  - 
TY  - JOUR
A1  - Diessner, J.
A1  - Bruttel, V.
A1  - Stein, R. G.
A1  - Horn, E.
A1  - Häusler, S. F. M.
A1  - Dietl, J.
A1  - Hönig, A.
A1  - Wischhusen, J.
T1  - Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
JF  - Cell Death & Disease
N2  - The antibody trastuzumab (Herceptin) has substantially improved overall survival for patients with aggressive HER2-positive breast cancer. However, about 70% of all treated patients will experience relapse or disease progression. This may be related to an insufficient targeting of the CD44(high)CD24(low) breast cancer stem cell subset, which is not only highly resistant to chemotherapy and radiotherapy but also a poor target for trastuzumab due to low HER2 surface expression. Hence, we explored whether the new antibody-drug conjugate T-DM1, which consists of the potent chemotherapeutic DM1 coupled to trastuzumab, could improve the targeting of these tumor-initiating or metastasis-initiating cells. To this aim, primary HER2-overexpressing tumor cells as well as HER2-positive and HER2-negative breast cancer cell lines were treated with T-DM1, and effects on survival, colony formation, gene and protein expression as well as antibody internalization were assessed. This revealed that CD44(high)CD24(low)HER2(low) stem cell-like breast cancer cells show high endocytic activity and are thus particularly sensitive towards the antibody-drug conjugate T-DM1. Consequently, preexisting CD44(high)CD24(low) cancer stem cells were depleted by concentrations of T-DM1 that did not affect the bulk of the tumor cells. Likewise, colony formation was efficiently suppressed. Moreover, when tumor cells were cocultured with natural killer cells, antibody-dependent cell-mediated cytotoxicity was enhanced, and EMT-mediated induction of stem cell-like properties was prevented in differentiated tumor cells. Thus our study reveals an unanticipated targeting of stem cell-like breast cancer cells by T-DM1 that may contribute to the clinical efficacy of this recently approved antibody-drug conjugate.
KW  - tumor stem cells
KW  - breast cancer
KW  - T-DM1
KW  - HER2
KW  - argeted therapy
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-119884
SN  - 2041-4889
VL  - 5
ER  -